Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/14656566.8.6.839
Reference63 articles.
1. Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
2. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis
3. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial;PLOS ONE;2016-01-05
2. New Active HIV-1 Protease Inhibitors Derived from 3-Hexanol: Conformation Study of the Free Inhibitors in Crystalline State and in Complex with the Enzyme;Chemical Biology & Drug Design;2012-03-07
3. Drug Resistance Pattern of HIV Type 1 Isolates Sampled in 2007 from Therapy-Naive Pregnant Women in North-Central Nigeria;AIDS Research and Human Retroviruses;2012-01
4. Tipranavir;Kucers' The Use of Antibiotics Sixth Edition;2010-10-29
5. Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy;Antimicrobial Agents and Chemotherapy;2010-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3